Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 5/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | REN | P00797 | 9/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14562986 | 0.96 | RAB9A (0.39) | RAB9ACTSLSMN1; SMN2CTSSCTSK | |
| SCHEMBL5421858 | 0.96 | RAB9A (0.39) | RAB9ACTSLSMN1; SMN2CTSSCTSK | |
| SCHEMBL14562963 | 0.94 | NPC1 (0.40) | RAB9ACTSLSMN1; SMN2CTSSCTSK | |
| SCHEMBL5424625 | 0.94 | NPC1 (0.40) | RAB9ACTSLSMN1; SMN2CTSSCTSK | |
| SCHEMBL5415710 | 0.94 | FAAH (0.39) | RAB9ACTSLSMN1; SMN2CTSSCTSK | |
| SCHEMBL14562931 | 0.94 | FAAH (0.39) | RAB9ACTSLSMN1; SMN2CTSSCTSK | |
| SCHEMBL5424719 | 0.93 | NPC1 (0.41) | RAB9ACTSLSMN1; SMN2CTSSCTSK | |
| SCHEMBL5419930 | 0.90 | L3MBTL1 (0.39) | RAB9ASMN1; SMN2CTSSCTSKLMNA | |
| SCHEMBL14562909 | 0.90 | L3MBTL1 (0.39) | RAB9ASMN1; SMN2CTSSCTSKLMNA | |
| SCHEMBL14562913 | 0.89 | NPC1 (0.39) | RAB9ASMN1; SMN2CTSSCTSKLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | claimed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| EP-1383748-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002051983-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | RAB9A 512/4885CTSL 11/4885SMN1; SMN2 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.